Results 1 to 10 of about 973,694 (311)

Nomogram for Predicting the Postoperative Venous Thromboembolism in Spinal Metastasis Tumor: A Multicenter Retrospective Study

open access: yesFrontiers in Oncology, 2021
IntroductionVenous thromboembolism can be divided into deep vein thrombosis and pulmonary embolism. These diseases are a major factor affecting the clinical prognosis of patients and can lead to the death of these patients.
Hao-ran Zhang   +10 more
doaj   +1 more source

MicroRNA‐215‐5p promotes proliferation, invasion, and inhibits apoptosis in liposarcoma cells by targeting MDM2

open access: yesCancer Medicine, 2023
Background Liposarcoma (LPS) is one of the most common soft tissue malignancies in adults, and it is characterized by dysregulation of multiple signaling pathways, including MDM2 proto‐oncogene (MDM2) amplification.
Zhengnan Song   +4 more
doaj   +1 more source

METTL3 stabilizes HDAC5 mRNA in an m6A-dependent manner to facilitate malignant proliferation of osteosarcoma cells

open access: yesCell Death Discovery, 2022
Osteosarcoma (OS) is a prevalent primary bone sarcoma. Methyltransferase-like 3 (METTL3) is dysregulated in human malignancies. This study explored the mechanism of METTL3 in OS cell proliferation.
Renbing Jiang   +5 more
doaj   +1 more source

Reprogramming tumor microenvironment via dual targeting co-delivery of regorafenib and alpha-difluoromethylornithine in osteosarcoma

open access: yesCancer Nanotechnology, 2023
Background Tumor angiogenesis, immunosuppression, and progression are all closely correlated with the tumor microenvironment (TME). Immune evasion is supported by both M2 phenotype tumor-associated macrophages (TAMs) and vascular aberrations in the TME ...
Hongsheng Wang   +14 more
doaj   +1 more source

Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells [PDF]

open access: yes, 2018
While bone is a frequent target of breast cancer-associated metastasis, little is known about the effects of tumor-bone interactions on the efficacy of tumor-suppressing agents.
Chen, Andy   +8 more
core   +1 more source

PTH1R-CaSR Cross Talk: New Treatment Options for Breast Cancer Osteolytic Bone Metastases. [PDF]

open access: yes, 2018
Metastatic breast cancer (BrCa) is currently incurable despite great improvements in treatment of primary BrCa. The incidence of skeletal metastases in advanced BrCa occurs up to 70%.
Wang, Bin, Yang, Yanmei
core   +2 more sources

Semaphorin 4D Promotes Skeletal Metastasis in Breast Cancer. [PDF]

open access: yes, 2016
Bone density is controlled by interactions between osteoclasts, which resorb bone, and osteoblasts, which deposit it. The semaphorins and their receptors, the plexins, originally shown to function in the immune system and to provide chemotactic cues for ...
Basile, John R   +6 more
core   +11 more sources

Intraoperative Extracorporeal Irradiation for the Treatment of the Meningioma-Infiltrated Calvarium. [PDF]

open access: yes, 2015
Objectives Complete removal of infiltrated bone is required to achieve a Simpson Grade 1 meningioma resection. Reconstruction of the resulting bone defect is typically achieved with a nonnative implant that can result in poor cosmesis, foreign body ...
Fragoso, Ruben   +3 more
core   +1 more source

Cellular and molecular mediators of bone metastatic lesions [PDF]

open access: yes, 2018
Bone is the preferential site of metastasis for breast and prostate tumor. Cancer cells establish a tight relationship with the host tissue, secreting factors that stimulate or inhibit bone cells, receiving signals generated from the bone remodeling ...
Battafarano, Giulia   +3 more
core   +2 more sources

Immunocytochemical Phenotyping of Disseminated Tumor Cells in Bone Marrow by uPA Receptor and CK18: Investigation of Sensitivity and Specificity of an Immunogold/Alkaline Phosphatase Double Staining Protocol [PDF]

open access: yes, 1997
Phenotyping of cytokeratin (CK) 18-positive cells in bone marrow is gaining increasing importance for future prognostic screening of carcinoma patients. Urokinase-type plasminogen activator receptor (uPA-R) is one example of a potential aggressive marker
Allgayer, Heike   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy